Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

Brief: Sartorius Stedim Biotech FY 2025 Sales Revenue EUR 2.97 Bln

Feb 3 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:

SARTORIUS STEDIM BIOTECH ACHIEVES CONSIDERABLE PROFITABLE GROWTH IN 2025 AND MAINTAINS POSITIVE OUTLOOK

SALES REVENUE RISES TO 2,967 MILLION EUROS, UP 9.6% CONSTANT CURRENCIES

NET PROFIT AT 266 MILLION EUROS

FOR FISCAL YEAR 2026, SARTORIUS STEDIM BIOTECH EXPECTS SALES REVENUE TO INCREASE BY BETWEEN AROUND 6 AND 10 PERCENT IN CONSTANT CURRENCIES

OUTLOOK 2026: UNDERLYING EBITDA MARGIN SHOULD INCREASE TO SLIGHTLY ABOVE 31 PERCENT

DUE TO CONTINUED HIGH DYNAMICS AND VOLATILITY ACROSS LIFE SCIENCE INDUSTRY, FORECAST REMAINS SUBJECT TO GREATER UNCERTAINTY, WHICH IS REFLECTED IN CURRENT FORECAST RANGE

FY 2025 EPS EUR 2.73

FY EBITDA OF 914 MILLION EUROS

FY 2025 FREE CASH FLOW EUR 294.5 MILLION

Source text: ID:nEQ3trH5Pa

Further company coverage: STDM.PA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))

Recent news on Sartorius Stedim Biotech SA

See all news